$IMLFF Epidermolysis Bullosa (EB) Development Program
Data generated in support of the EB program demonstrate that INM-750 may have a significant impact on the symptoms of EB (including accelerated wound healing and a reduction in inflammation, pain (and itch), and act as an anti-bacterial agent). Additionally, our data indicate that INM-750 may have an impact on the underlying disease by increasing keratin production in the skin. Key vendors to support the INM-750 development program have been identified and, in conjunction with access to additional funding in early 2017, we will move quickly to execute on our game plan of optimizing the final formulation, conducting key pre-clinical toxicology (safety) studies, and identifying clinical sites for the initial human clinical trial(s).
